Major Depressive Disorder
Major Depressive Disorder (MDD), also known as clinical or major depression, is a severe mental health condition characterized by at least two weeks of persistent low mood, low self-esteem, and a lack of interest or pleasure in everyday activities, and may involve symptoms such as sadness, angry outbursts, fatigue, feelings of worthlessness, difficulty thinking, and thoughts of suicide. Introduced by US clinicians in the mid-1970s and recognized in the DSM-III by the American Psychiatric Association, MDD is a significant mood disorder impacting daily functioning.
Health Outcomes
- Achieved Remission
- Alleviated D-Tryptophan Levels
- Altered Monoamine Signaling
- Altered Neurobiological Markers
- Changed Functional Connectivity
- Decreased Composite Scores
- Enhanced Neurogenesis in Adults
- Improved Antidepressant Response
- Improved Antidepressant Support
- Improved Brain-Derived Neurotrophic Factor Level
- Improved Catecholamine Status
- Improved Cognitive Reactivity to Sad Mood
- Improved Depression Severity
- Improved Depression Status
- Improved Depressive Symptoms
- Improved Depressive-Like Behaviours
- Improved Distress of Life Score
- Improved Emotional Behavior
- Improved Emotional Function
- Improved Emotional Processing
- Improved Emotional State
- Improved Emotional Well-Being Quality of Life
- Improved Emotional Well-being
- Improved Fatigue Index
- Improved General Behavioral Scores
- Improved Global Clinical Impression
- Improved Global Clinical Status
- Improved Global Improvement of Symptoms (Clinician-Rated)
- Improved Global Symptom
- Improved Glucocorticoid Negative Feedback on the HPA Axis
- Improved Gut-Brain Axis Related Neurobehavioral Measures
- Improved Gut-Brain Axis-Related Neuropsychiatric Health
- Improved Medication Adherence
- Improved Mental Health
- Improved Mood
- Improved Mood Disturbance
- Improved Neuroendocrine Stress Markers
- Improved Neuropsychiatric Outcomes
- Improved Neurotransmitter Metabolism
- Improved Neurotrophic Signaling
- Improved Parental Mood
- Improved Pattern Separation
- Improved Perceived Mental Well-being
- Improved Positive Affect
- Improved Positive Mood States
- Improved Positive Well-Being
- Improved Problem-Solving Skills
- Improved Psychological Distress
- Improved Psychological Status
- Improved Psychological Well-being
- Improved Psychosocial Domain Score
- Improved Psychosocial Health-Related Quality of Life
- Improved Quality of Life
- Improved Remission Rate
- Improved Responder Rate
- Improved Response Rate
- Improved Role Emotional
- Improved Self-Rated Vigor
- Improved Serotonin Metabolism
- Improved Set-Shifting Reaction Time
- Improved Stress-Related Psychiatric Health
- Improved Subjective Recovery
- Improved Subjective Satisfaction
- Improved Synaptic Plasticity
- Improved Total DASS-42 Score
- Improved Treatment Efficacy
- Improved Vigor
- Increased 3-Hydroxykynurenine to Kynurenine Ratio
- Increased Brain-derived Neurotrophic Factor Level
- Increased Clinical Response Proportion
- Increased GABAergic Signaling
- Increased Heart Rate Variability
- Increased Insomnia
- Increased Neurogenesis
- Increased Plasma Serotonin Levels
- Increased Remission Rate
- Increased Serum BDNF Levels
- Increased Systemic GABA Levels
- Increased Time in Bed
- Increased Treatment Effectiveness
- Increased Treatment Response
- Increased Weight Gain Rate
- Maintained Lower Salivary Cortisol Levels
- Modulated HPA Axis
- No CYP1A2 or CYP3A4 Interaction
- No Change in Plasma GABA Levels
- Normalized HPA Axis Activity
- Reduced 5-Hydroxytryptamine Level
- Reduced Abnormal Brain Plasticity Due to Stress
- Reduced Anhedonia
- Reduced Anthranilic Acid Level
- Reduced Anxiety and Depression (HADS)
- Reduced Appetite
- Reduced Appetite Changes
- Reduced Bifidobacterium and Lactobacillus Counts in Patients with MDD
- Reduced Chocolate Pleasantness Rating
- Reduced Cortical Excitation
- Reduced D-Tryptophan Levels
- Reduced DASS-21 Score
- Reduced Depressed Mood
- Reduced Depression
- Reduced Depression Anxiety Stress Symptoms
- Reduced Depression Score
- Reduced Depression Scores at Follow-Up
- Reduced Depression Severity
- Reduced Depression Symptoms
- Reduced Depression and Anxiety Scores
- Reduced Depression-like Behavior
- Reduced Depressive Affect
- Reduced Depressive Behavior
- Reduced Depressive Symptom
- Reduced Depressive Thoughts
- Reduced Despair-Like Behavior
- Reduced Glabellar Lines
- Reduced Global Symptom Persistence
- Reduced Global Symptoms
- Reduced HADS Global Score
- Reduced Hamilton Depression Rating Scale Score
- Reduced Hippocampal Apoptosis
- Reduced Hyperactivity of the Hypothalamic-Pituitary-Adrenal Axis
- Reduced Incidence of Crying
- Reduced Interference with Daily Life
- Reduced Irritability
- Reduced Kynurenine Level
- Reduced Mental Fatigue
- Reduced Mental Health Symptom
- Reduced Mood Disturbance
- Reduced N-acetylaspartate Level
- Reduced Negative Emotional Responses
- Reduced Negative Mood States
- Reduced Perceived Stress
- Reduced Prefrontal Cortex Activation
- Reduced Prospective Consumption
- Reduced Psychiatric Problems
- Reduced Psychological Distress
- Reduced Psychological Score
- Reduced Psychopathology Symptoms
- Reduced Psychosocial Symptom
- Reduced Relapse Rate
- Reduced Relative Abundance of Coprococcus Genus
- Reduced Risk of Crying
- Reduced Salivary Alpha-Amylase Activity
- Reduced Serum Kynurenine Levels
- Reduced Sleep Duration
- Reduced Stress-Induced Reduction in Diurnal Temperature Amplitude
- Reduced Symptoms
- Reduced Total Mood Disturbance
- Reduced Total Score on Depression Anxiety Stress Scales (DASS-42)
- Reduced VIA Positivity
- Stable Brain Metabolite Levels
- Worsened Depression Score